SCS wins media patent
Thursday, 10 July, 2008
Stem Cell Sciences [ASX: STC] has been granted a UK Patent Office patent for the company's new range of stem cell culture media.
The patent covers the company's Culticell iSTEM range, which contains a combination of enzyme inhibitors. The range is based on technology described in Nature recently by stem cell research pioneer Professor Austin Smith, now at Cambridge University, who is chair of the company's scientific advisory board.
Smith discovered that with the inhibition of key enzymes in specific combinations it is possible to produce pluripotent stem cells without feeder cells, growth factors, leukaemia inhibitory factor or serum.
The patent covers every use of the media, including use of the media for cultivating stem cells.
COVID vaccine candidate protects against multiple variants
By targeting features shared by a range of coronaviruses, the vaccine is designed to offer...
Stevia leaf extract has potential as an anticancer treatment
When fermented with bacteria isolated from banana leaves, stevia extract kills off pancreatic...
Even non-antibiotics can disrupt the microbiome
Many non-antibiotics inhibit useful gut bacteria, giving rise to an imbalance in the microbiome,...
